Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

被引：1
|
作者：
Schuler, M. [1 ]
Yang, J. [2 ,3 ]
Sequist, L. V. [4 ,5 ]
Yamamoto, N. [6 ]
Zhou, C. [7 ]
O'Byrne, K. [8 ,9 ]
Hirsh, V. [10 ]
Mok, T. [11 ]
Shah, R. [12 ]
Wu, Y. -L. [13 ,14 ]
机构：
[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Natl Taiwan Univ, Taipei, Taiwan
[4] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA USA
[6] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[7] Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China
[8] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia
[9] Queensland Univ Technol, Brisbane, Qld, Australia
[10] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[11] Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China
[12] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
[13] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[14] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(16)30248-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138PD
引用
收藏
页码：S116 / S117
页数：2
相关论文
共 50 条
  • [21] Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR- Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program
    Tu, Hai-Yan
    Wu, Yi-Long
    ONCOTARGETS AND THERAPY, 2020, 13 : 12539 - 12547
  • [22] Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
    Kato, Terufumi
    Yoshioka, Hiroshige
    Okamoto, Isamu
    Yokoyama, Akira
    Hida, Toyoaki
    Seto, Takashi
    Kiura, Katsuyuki
    Massey, Dan
    Seki, Yoko
    Yamamoto, Nobuyuki
    CANCER SCIENCE, 2015, 106 (09) : 1202 - 1211
  • [23] Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7
    Yang, J. C-H.
    Wu, Y-L.
    Hirsh, V.
    O'Byrne, K.
    Yamamoto, N.
    Popat, S.
    Tamiya, A.
    Maerten, A.
    Schuler, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S84 - S85
  • [24] EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
    Wu, Yi-Long
    Sequist, Lecia V.
    Hu, Cheng-Ping
    Feng, Jifeng
    Lu, Shun
    Huang, Yunchao
    Li, Wei
    Hou, Mei
    Schuler, Martin
    Mok, Tony
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Hirsh, Vera
    Gibson, Neil
    Massey, Dan
    Kim, Miyoung
    Yang, James Chih-Hsin
    BRITISH JOURNAL OF CANCER, 2017, 116 (02) : 175 - 185
  • [25] EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6
    Yi-Long Wu
    Lecia V Sequist
    Cheng-Ping Hu
    Jifeng Feng
    Shun Lu
    Yunchao Huang
    Wei Li
    Mei Hou
    Martin Schuler
    Tony Mok
    Nobuyuki Yamamoto
    Kenneth O'Byrne
    Vera Hirsh
    Neil Gibson
    Dan Massey
    Miyoung Kim
    James Chih-Hsin Yang
    British Journal of Cancer, 2017, 116 : 175 - 185
  • [26] Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
    Hirsh, V.
    Park, K.
    Tan, E. H.
    Zhang, L.
    O'Byrne, K.
    Boyer, M.
    Yang, J. C. H.
    Mok, T.
    Lee, K. H.
    Lu, S.
    Shi, Y.
    Kim, S. W.
    Laskin, J.
    Kim, D. W.
    Laurie, S. A.
    Kolbeck, K.
    Fan, J.
    Dodd, N.
    Maerten, A.
    Paz-Ares, L.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S184 - S184
  • [27] Afatinib for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: clinical implications of the LUX-Lung 7 study
    Park, Keunchil
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4 (23)
  • [28] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [29] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Dickgreber, Nicolas J.
    Halmos, Balazs
    Hirsh, Vera
    Hochmair, Maximilian J.
    Levy, Benjamin Philip
    De Marinis, Filippo
    Mok, Tony
    O'Byrne, Kenneth
    Okamoto, Isamu
    Schuler, Martin H.
    Sebastian, Martin
    Shah, Riyaz N. H.
    Tan, Eng-Huat
    Yamamoto, Nobuyuki
    Marten, Angela
    Massey, Dan
    Wind, Sven
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
    Passaro, A.
    Yang, J. C.
    Ahn, M.
    Dickgreber, N. J.
    Halmos, B.
    Hirsh, V.
    Hochmair, M. J.
    Levy, B. P.
    de Marinis, F.
    Mok, T.
    O'Byrne, K.
    Okamoto, I.
    Schuler, M.
    Sebastian, M.
    Shah, R.
    Tan, E.
    Yamamoto, N.
    Maerten, A.
    Wind, S.
    Carbone, D. P.
    ANNALS OF ONCOLOGY, 2015, 26 : 77 - 77
12345